GoPath Diagnostics

02/19/2026

The GoPath team is heading to San Antonio for the 115th Annual USCAP Meeting next month! 🎯

Stop by booth 456 to see how our advanced pathology and molecular diagnostic solutions can elevate your practice.

🔬 Comprehensive Testing: Molecular, FISH, flow cytometry, histology, and cytology, all from one trusted partner.
🧬 GeneticsNow® Panels: Actionable NGS results for hereditary cancer risk assessment.
🩸 Subspecialty Pathology Expertise: GI, GU, Hematopathology, and Dermatopathology with integrated IHC and molecular insights.
💡 Biopharma Support: Contract research and central lab services customized for clinical trials and regulatory success.

Learn more at https://www.gopathdx.com/uscap-26

02/17/2026

Happy Lunar New Year 🐎✨

Wishing you prosperity, good health, and momentum as we welcome the Year of the Horse in 2026. May this new year bring steady progress, strong partnerships, and new growth opportunities.🌟

02/12/2026

How can communication help those living with hereditary cancer risk?

University of South Florida professor Dr. Marleah Dean Kruzel partners with the CDC to raise awareness through personal storytelling and research on genetic risk communication. Her work sheds light on the unique experiences of “previvors” and the importance of support after genetic testing.

Read more from the USF College of Arts and Sciences about how her mission is helping others navigate uncertainty and make informed health decisions:

University of South Florida

02/10/2026

Understanding breast self-awareness is an important part of early cancer detection. Experts say it’s about knowing how your breasts normally look and feel so you can notice changes early. Learn why doctors are encouraging self-awareness alongside regular mammograms to support prevention.

Read more from the AP:

Breast self-awareness is a more flexible approach to preventing breast cancer that goes along with other essential screening measures.

02/04/2026

💪 Prevention starts with action, and it can save lives. Nearly 40% of cancer cases are linked to preventable causes like smoking, excess weight, and physical inactivity.

This February, during National Cancer Prevention Month, let’s recommit to healthier habits that lower our risk of cancer. Small steps like staying active, eating well, and protecting your skin can make a big difference.

Learn more from the American Association for Cancer Research (AACR): https://www.aacr.org/patients-caregivers/awareness-months/national-cancer-prevention-month/

An estimated 40 percent of all cancers diagnosed and nearly half of all cancer deaths in the U.S. can be attributed to preventable causes.

01/30/2026

More people are living longer after cancer than ever before. 🌟

Today, 7 in 10 people diagnosed with cancer live at least 5 years after their diagnosis, a major leap from the 1970s. Thanks to advancements in research, treatment, and earlier detection, even late-stage cancers are experiencing improved survival rates. Every statistic represents more birthdays, more family moments, and more hope for the future.

Read more from the American Cancer Society:

Milestone in cancer survival: 7 in 10 people reach the 5-year mark

01/28/2026

What if a single germline variant could reshape how you think about prostate cancer hormone therapy?

A new GoPath study examines the HSD3B1 (1245C) adrenal‑permissive allele in 631 patients, where nearly 40% carried at least one copy and over 7% were homozygous. It outlines how genotype insights can inform expectations for androgen deprivation therapy and long‑term hormonal strategies. Read the full article to explore how incorporating germline testing may support more individualized prostate cancer management.

Read more: https://www.gopathdx.com/blog/tpost/f459a6g9r1-prevalence-of-the-hsd3b1-1245c-variant-a

01/26/2026

What if a routine stain from your own lab could change 1 in 8 prostate core diagnoses?

Our new GoPath study, presented at the 101st Annual Meeting of the Western Section of the AUA, shows that adding PIN4 to all prostate needle cores often upgrades or refines initial H&E findings. The blog walks through shifts between benign, ASAP/HGPIN, adenocarcinoma, and changes in reported tumor extent. Read now to see how routine use of PIN4 can support clearer risk stratification and more confident treatment planning in your practice.

Read more: https://www.gopathdx.com/blog/tpost/f459a6g9r1-prevalence-of-the-hsd3b1-1245c-variant-a

01/22/2026

Prostate cancer tumor burden may be higher than it looks on your reports.

A new GoPath study, presented in part at the 101st Annual Meeting of the Western Section of the AUA, shows that using slide core length instead of gross core length can shift percent tumor involvement from 54.79% to 75.52% in the same biopsy cores. The blog details how this discrepancy affects common thresholds such as the 50% involvement cut‑off in Gleason 3+3 and 3+4 disease, with direct impact on active surveillance decisions. The study outlines practical steps for clinicians and pathologists to standardize slide‑based measurements and improve confidence in risk stratification.

Read more: https://www.gopathdx.com/blog/tpost/yvjt72xy41-the-difference-of-percent-tumor-involvem

01/14/2026

A new study shows that expanding genetic testing beyond family history can identify more women at risk for breast cancer. Researchers found that criteria-independent testing detected pathogenic variants in women who had no personal or family history of the disease. This approach may help clinicians catch risk factors earlier and improve prevention efforts.

Read more:

Criteria-independent genetic testing identifies more women with pathogenic breast cancer variants than guideline-based approaches.

01/09/2026

We’re often asked how genetic testing can impact a prostate cancer journey and which patients benefit most. ProstateNow™ provides clarity by analyzing inherited risk factors that inform prognosis and potential targeted therapy options.

To learn more about the genes we evaluate and how these results can personalize your treatment plan, visit: https://geneticsnow.com/prostatenow

01/07/2026

Colorectal cancer is increasingly being diagnosed during pregnancy and the postpartum period, often at later stages with worse outcomes. New research highlights how immune and inflammatory changes in pregnancy may mask symptoms, fuel tumor growth, and complicate treatment decisions, while emerging screening tools like ctDNA methylation assays could improve early detection for high-risk patients.

Read more:

Colorectal cancer diagnosed during pregnancy is an increasing concern as the incidence of colorectal cancer continues to rise among young adults. Immunological adaptations of pregnancy may promote more aggressive tumor characteristics, helping to explain the less favorable outcomes associated with c...